vs
Side-by-side financial comparison of Evercore Inc. (EVR) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.4B, roughly 1.7× Evercore Inc.). Zoetis runs the higher net margin — 25.3% vs 23.0%, a 2.2% gap on every dollar of revenue. On growth, Evercore Inc. posted the faster year-over-year revenue change (100.3% vs 3.0%). Over the past eight quarters, Evercore Inc.'s revenue compounded faster (42.2% CAGR vs 4.4%).
Evercore Inc., formerly known as Evercore Partners, is a global independent investment banking advisory firm founded in 1995 by Roger Altman, David Offensend, and Austin Beutner. The firm has advised on over $4.7 trillion of merger, acquisition, and restructuring transactions since its founding.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
EVR vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $2.4B |
| Net Profit | $322.7M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | — | 31.9% |
| Net Margin | 23.0% | 25.3% |
| Revenue YoY | 100.3% | 3.0% |
| Net Profit YoY | 106.1% | 3.8% |
| EPS (diluted) | $7.20 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.3B | $2.4B | ||
| Q3 25 | $1.0B | $2.4B | ||
| Q2 25 | $838.0M | $2.5B | ||
| Q1 25 | $699.0M | $2.2B | ||
| Q4 24 | $979.5M | $2.3B | ||
| Q3 24 | $738.4M | $2.4B | ||
| Q2 24 | $693.4M | $2.4B |
| Q1 26 | $322.7M | — | ||
| Q4 25 | $204.0M | $603.0M | ||
| Q3 25 | $144.6M | $721.0M | ||
| Q2 25 | $97.2M | $718.0M | ||
| Q1 25 | $146.2M | $631.0M | ||
| Q4 24 | $140.4M | $581.0M | ||
| Q3 24 | $78.4M | $682.0M | ||
| Q2 24 | $73.8M | $624.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | — | — | ||
| Q4 25 | 24.2% | 31.9% | ||
| Q3 25 | 20.8% | 37.0% | ||
| Q2 25 | 18.0% | 36.7% | ||
| Q1 25 | 16.0% | 36.5% | ||
| Q4 24 | 21.8% | 31.6% | ||
| Q3 24 | 16.7% | 36.6% | ||
| Q2 24 | 15.9% | 33.0% |
| Q1 26 | 23.0% | — | ||
| Q4 25 | 15.7% | 25.3% | ||
| Q3 25 | 13.8% | 30.0% | ||
| Q2 25 | 11.6% | 29.2% | ||
| Q1 25 | 20.9% | 28.4% | ||
| Q4 24 | 14.3% | 25.1% | ||
| Q3 24 | 10.6% | 28.6% | ||
| Q2 24 | 10.6% | 26.4% |
| Q1 26 | $7.20 | — | ||
| Q4 25 | $4.80 | $1.37 | ||
| Q3 25 | $3.41 | $1.63 | ||
| Q2 25 | $2.36 | $1.61 | ||
| Q1 25 | $3.48 | $1.41 | ||
| Q4 24 | $3.32 | $1.29 | ||
| Q3 24 | $1.86 | $1.50 | ||
| Q2 24 | $1.81 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $3.3B |
| Total Assets | — | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $2.4B | $2.1B | ||
| Q2 25 | $1.7B | $1.4B | ||
| Q1 25 | $1.4B | $1.7B | ||
| Q4 24 | $2.4B | $2.0B | ||
| Q3 24 | $1.8B | $1.7B | ||
| Q2 24 | $1.7B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $3.3B | ||
| Q3 25 | $1.8B | $5.4B | ||
| Q2 25 | $1.7B | $5.0B | ||
| Q1 25 | $1.5B | $4.7B | ||
| Q4 24 | $1.7B | $4.8B | ||
| Q3 24 | $1.6B | $5.2B | ||
| Q2 24 | $1.5B | $5.0B |
| Q1 26 | — | — | ||
| Q4 25 | $5.4B | $15.5B | ||
| Q3 25 | $4.4B | $15.2B | ||
| Q2 25 | $3.7B | $14.5B | ||
| Q1 25 | $3.3B | $14.1B | ||
| Q4 24 | $4.2B | $14.2B | ||
| Q3 24 | $3.6B | $14.4B | ||
| Q2 24 | $3.3B | $14.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $807.5M | $893.0M | ||
| Q3 25 | $560.9M | $938.0M | ||
| Q2 25 | $437.7M | $486.0M | ||
| Q1 25 | $-549.7M | $587.0M | ||
| Q4 24 | $686.4M | $905.0M | ||
| Q3 24 | $234.5M | $951.0M | ||
| Q2 24 | $348.5M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | $798.6M | $732.0M | ||
| Q3 25 | $541.5M | $805.0M | ||
| Q2 25 | $411.7M | $308.0M | ||
| Q1 25 | $-569.3M | $438.0M | ||
| Q4 24 | $673.1M | $689.0M | ||
| Q3 24 | $226.6M | $784.0M | ||
| Q2 24 | $340.7M | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | 61.6% | 30.7% | ||
| Q3 25 | 51.8% | 33.5% | ||
| Q2 25 | 49.1% | 12.5% | ||
| Q1 25 | -81.4% | 19.7% | ||
| Q4 24 | 68.7% | 29.7% | ||
| Q3 24 | 30.7% | 32.8% | ||
| Q2 24 | 49.1% | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | 6.7% | ||
| Q3 25 | 1.9% | 5.5% | ||
| Q2 25 | 3.1% | 7.2% | ||
| Q1 25 | 2.8% | 6.7% | ||
| Q4 24 | 1.4% | 9.3% | ||
| Q3 24 | 1.1% | 7.0% | ||
| Q2 24 | 1.1% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | 3.96× | 1.48× | ||
| Q3 25 | 3.88× | 1.30× | ||
| Q2 25 | 4.50× | 0.68× | ||
| Q1 25 | -3.76× | 0.93× | ||
| Q4 24 | 4.89× | 1.56× | ||
| Q3 24 | 2.99× | 1.39× | ||
| Q2 24 | 4.72× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EVR
| Advisory Fees (1) | $1.2B | 89% |
| Commissions and Related Revenue | $62.7M | 4% |
| Underwriting Fees | $55.1M | 4% |
| Asset Management and Administration Fees (2) | $23.7M | 2% |
| Other Revenue, net | $15.4M | 1% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
